NEW YORK – Late-stage biotech company CytoDyn announced on Monday that an early trial of its new drug candidate leronlimab (PRO 140) produced a positive clinical response in two patients with metastatic breast cancer.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.